Treatment of the hemophilias. Curr Opin Hematol 1995 Sep;2(5):386-94
Date
09/01/1995Pubmed ID
9372024DOI
10.1097/00062752-199502050-00010Scopus ID
2-s2.0-0029361553 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
The treatment of hemophilia and conditions that frequently afflict hemophilic patients, such as arthropathy, HIV infection, and viral hepatitis, are discussed. Long-term prophylaxis with Factor VIII or IX is very successful at preventing disabling arthropathy. Much research is being done on gene therapy and prolonged periods of Factor VIII and IX expression have already been achieved in animals. In HIV-seropositive hemophilic patients the CD4 count appears to decline more slowly in patients treated with higher purity than with lower-purity products. Thermoresistant non-lipid-enveloped viruses, such as parvovirus, do not become inactivated by the currently used virucidal methods.
Author List
Moll S, White GC 2ndAuthor
Gilbert C. White MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Blood Coagulation FactorsCreutzfeldt-Jakob Syndrome
Genetic Therapy
Hemophilia A
Hemorrhage
Hepatitis, Viral, Human
Humans
Transfusion Reaction
Virus Diseases